CRISPR Therapeutics AG (CRSP) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$57.85

From 52W high−26.33%

Volume3.35M

Market cap$5.47B

P/E (TTM)—

P/S (TTM)408.4x

Div yield—

Key dataSep 18, 2026

Open

$57.85

From 52W high

−26.33%

Volume

3.35M

Market cap

$5.47B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−8.6x

P/E (TTM)

—

RSI (14)

53.7

MomentumView details →

1D Return

−1.33%

YTD Return

+6.85%

SummaryUpdated Jun 1, 2026

CRISPR Therapeutics AG (NASDAQ:CRSP) is a Swiss-based gene editing company founded in 2013 that develops gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform technology. The company went public in October 2016 and has emerged as one of the leading players in the rapidly evolving field of gene editing therapeutics. CRISPR Therapeutics focuses on creating treatments for conditions ranging from blood disorders to cancer and diabetes, with its lead therapy CTX001 representing one of the first CRISPR-based treatments to advance through clinical trials toward potential regulatory approval.

Ask drillr about CRISPR Therapeutics AG →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−8.6x

EV/Sales

290.3x

P/S (TTM)

408.4x

P/B (TTM)

3.1x

ProfitabilityView details →

Gross Margin

−1534.39%

Net Margin

−3368.72%

EBITDA Margin

−3390.05%

ROE (TTM)

−25.83%

ROA (TTM)

−17.02%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−63.57%

EPS YoY

+12.34%

FCF YoY

−47.66%

Revenue CAGR 3Y

+100.42%

EPS CAGR 3Y

−49.08%

EBITDA YoY

+8.83%

MomentumView details →

1D Return

−1.33%

YTD Return

+6.85%

1Y Return

−10.09%

RSI (14)

53.7

vs 50D SMA

+5.68%

vs 200D SMA

+5.09%

Capital & dividendView details →

Debt/Equity

0.45x

Current Ratio

17.85x

Quick Ratio

17.85x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.94

EPS Surprise

21.01%

Beats (12Q)

6/12

Next Q EPS Est

−$1.05

Avg Surprise (4Q)

416.68%

Rev Surprise

36.69%

Financials snapshotView financials →

Revenue (TTM)

13.39M

Net Income (TTM)

−451.14M

Op. CF (TTM)

−478.48M

Next earningsNov 9, 2026 →

Latest newsMore news →

CRISPR Therapeutics AG (CRSP) shares closed at $51.80, down 2.19% from the previous trading session, underperforming the S&P 500's 0.45% decline.5d ago

CRISPR Therapeutics AG elected Samarth Kulkarni as Chairman of the Board of Directors and Ali Behbahani, Maria Fardis, H. Edward Fleming Jr., and Simeon J. George as members of the Board of Directors, effective June 4, 2026.109d ago

Similar companies

Cogent Biosciences, Inc.COGT PTC Therapeutics, Inc.PTCT Dianthus Therapeutics, Inc.DNTH CK Life Sciences Int'l., (Holdings) Inc.00775.HK Ligand Pharmaceuticals IncorporatedLGND Scholar Rock Holding CorporationSRRK Find similar companies →

Latest newsMore news →

CRISPR Therapeutics AG (CRSP) shares closed at $51.80, down 2.19% from the previous trading session, underperforming the S&P 500's 0.45% decline.5d ago CRISPR Therapeutics AG elected Samarth Kulkarni as Chairman of the Board of Directors and Ali Behbahani, Maria Fardis, H. Edward Fleming Jr., and Simeon J. George as members of the Board of Directors, effective June 4, 2026.109d ago